Literature DB >> 19322629

The combination topotecan, temozolomide and dexamethasone associated with radiotherapy as treatment of central nervous system myeloma relapse.

Ombretta Annibali1, Carolina Nobile2, Rosa Greco2, Francesco Cellini3, Carlo Cosimo Quattrocchi4, Maria Cristina Tirindelli2, Maria Teresa Petrucci5, Giuseppe Avvisati2.   

Abstract

A 46-year-old woman with IgA-lambda myeloma in partial remission, after a tandem autologous hematopoietic stem cells transplantation, complained of progressive lower back pain associated with paraplegia and neurological bladder 6 months after the second transplant. A lumbar puncture revealed atypical malignant plasma cells in the cerebral spinal fluid associated with multiple foci of altered signal intensity of brain and spinal cord demonstrated by magnetic resonance. Considering the lack of efficacious chemotherapies for neurological myeloma, an experimental systemic treatment with topotecan, temozolamide, and dexamethasone associated with concurrent radiotherapy of brain and spinal cord was initiated. During this treatment, the patient rapidly improved with disappearance of back pain, paresthesia, and urinary incontinence lasting 5 months, before dying of progressive disease. The proposed systemic chemotherapy associated with concurrent radiotherapy may have an antitumor activity against MM with CNS involvement.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19322629     DOI: 10.1007/s12185-009-0277-6

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  21 in total

1.  Topotecan--a new treatment option in the therapy of brain metastases of lung cancer.

Authors:  W Schütte; C Manegold; J V von Pawel; J Lan; B Schäfer; S Kaubitzsch; H J Staab
Journal:  Front Radiat Ther Oncol       Date:  1999

2.  Phase II study of topotecan and cyclophosphamide in patients with relapsed and refractory multiple myeloma.

Authors:  Eric H Kraut; Donn Young; Sherif Farag; Arthur G James; Richard J Solove
Journal:  Leuk Res       Date:  2005-04-01       Impact factor: 3.156

3.  Temozolomide-mediated radiation enhancement in glioblastoma: a report on underlying mechanisms.

Authors:  Arnab Chakravarti; Michael G Erkkinen; Ulf Nestler; Roger Stupp; Minesh Mehta; Ken Aldape; Mark R Gilbert; Peter McL Black; Jay S Loeffler
Journal:  Clin Cancer Res       Date:  2006-08-01       Impact factor: 12.531

Review 4.  Myeloma of the central nervous system: association with high-risk chromosomal abnormalities, plasmablastic morphology and extramedullary manifestations.

Authors:  Athanasios B-T Fassas; Firas Muwalla; Tanya Berryman; Riad Benramdane; Lija Joseph; Elias Anaissie; Rajesh Sethi; Raman Desikan; David Siegel; Ashraf Badros; Amir Toor; Maurizio Zangari; Christopher Morris; Edgardo Angtuaco; Sajini Mathew; Carla Wilson; Aubrey Hough; Sami Harik; Bart Barlogie; Guido Tricot
Journal:  Br J Haematol       Date:  2002-04       Impact factor: 6.998

Review 5.  Temozolomide in combination with other cytotoxic agents.

Authors:  M Prados
Journal:  Semin Oncol       Date:  2001-08       Impact factor: 4.929

Review 6.  Temozolomide, a novel alkylating agent with activity in the central nervous system, may improve the treatment of advanced metastatic melanoma.

Authors:  S S Agarwala; J M Kirkwood
Journal:  Oncologist       Date:  2000

7.  Phase I study of topotecan plus cranial radiation for glioblastoma multiforme: results of Radiation Therapy Oncology Group Trial 9507.

Authors:  B J Fisher; C Scott; D R Macdonald; C Coughlin; W J Curran
Journal:  J Clin Oncol       Date:  2001-02-15       Impact factor: 44.544

Review 8.  Temozolomide and treatment of malignant glioma.

Authors:  H S Friedman; T Kerby; H Calvert
Journal:  Clin Cancer Res       Date:  2000-07       Impact factor: 12.531

9.  O6-methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells.

Authors:  Mirjam Hermisson; Andrea Klumpp; Wolfgang Wick; Jörg Wischhusen; Georg Nagel; Wynand Roos; Bernd Kaina; Michael Weller
Journal:  J Neurochem       Date:  2006-01-09       Impact factor: 5.372

10.  Phase II study of topotecan plus cranial radiation for glioblastoma multiforme: results of Radiation Therapy Oncology Group 9513.

Authors:  Barbara Fisher; M Won; David Macdonald; Douglas W Johnson; Wilson Roa
Journal:  Int J Radiat Oncol Biol Phys       Date:  2002-07-15       Impact factor: 7.038

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.